Chatziioannou, Eftychia http://orcid.org/0000-0002-7843-7160
Leiter, Ulrike
Thomas, Ioannis
Keim, Ulrike
Seeber, Olivia
Meiwes, Andreas
Boessenecker, Isabell
Gonzalez, Stephanie Sanchez
Torres, Francisco Merraz
Niessner, Heike
Sinnberg, Tobias
Forschner, Andrea
Flatz, Lukas
Amaral, Teresa http://orcid.org/0000-0002-2516-5181
Funding for this research was provided by:
Universitätsklinikum Tübingen
Article History
Accepted: 25 March 2023
First Online: 4 May 2023
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL.
: Ulrike Leiter reports research support from MSD; consulting fees and honoraria from Sun Pharma, Sanofi (personal and institutional), MSD (personal and institutional), Novartis, Roche, and Almirall Hermal; support for attending meetings from Sun Pharma; and participation on a Data Safety Monitoring Board or Advisory Board from Sun Pharma, Sanofi, MSD, Novartis, Roche, and Almirall Hermal, outside the submitted work. Ioannis Thomas reports honoraria for talks or advisory boards from BMS and Pierre Fabre; and research funding (institutional) from BMS, Pfizer, MSD, Amgen, ARGN-X, LEO, Novartis, UCB, 4SC, AstraZeneca, BioNTech, Genentech, Roche, Biotech, CureVac, HUYA, Incyte, Idera, Iovance, InflaRx, Cerpass, Kartos, Nektar, Philogen, Pierre Fabre, Regeneron, Replimune, and Sanofi. Heike Niessner reports institutional funding from Novartis and Pierre Fabre outside the submitted work. Tobias Sinnberg reports institutional funding from Novartis and Pierre Fabre outside the submitted work. Andrea Forschner served as a consultant to Roche, Novartis, MSD, BMS, and Pierre Fabre; received travel support from Roche, Novartis, BMS, and Pierre Fabre; received speaker fees from Roche, Novartis, BMS, MSD, and CeGaT; and reports institutional research grants from BMS Stiftung Immunonkologie. Lukas Flatz reports grants or contracts from Hookipa Pharma, SAKK/Immunophotonics, DFG Grant (Deutsche Forschungsgemeinschaft), Philogen, and Mundipharma; consulting fees from Philogen, Sanofi, Novartis, and BMS; participation on the Data Safety Board, University of Basel; and stocks or stock options from Hookipa Pharma, outside the submitted work. Teresa Amaral reports personal honoraria from BMS, CeCaVa, Novartis, and Pierre Fabre; institutional financial support from iFIT, NeraCare, Novartis, Sanofi, and SkylineDx, and an institutional research grant from Novartis, outside the submitted work. Eftychia Chatziioannou, Ulrike Keim, Olivia Seeber, Andreas Meiwes, Isabell Boessenecker, Stephanie Sanchez Gonzalez, and Francisco Merraz Torres have no relationships to disclose.
: The Ethics Commission of the Eberhard Karls University Tuebingen approved this retrospective single-center study (number 676/2016BO2).
: Patients provided informed consent to be enrolled in the CMMR and for the use of their clinical data.
: Not applicable.
: The data supporting the findings of this study are available from the corresponding author upon reasonable request.
: Not applicable.
: Study concept: EC, TA. Data collection: EC, TS, HN, TA. Data analysis: EC, TA. Data interpretation: All authors. Writing: All authors. Final approval: All authors. All authors agree to be accountable for all aspects of this work.